RAD001 + Exemestane
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Oestrogen Receptor Positive Advanced Breast Cancer
Conditions
Oestrogen Receptor Positive Advanced Breast Cancer
Trial Timeline
Jan 31, 2013 → Aug 15, 2016
NCT ID
NCT01743560About RAD001 + Exemestane
RAD001 + Exemestane is a approved stage product being developed by Novartis for Oestrogen Receptor Positive Advanced Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01743560. Target conditions include Oestrogen Receptor Positive Advanced Breast Cancer.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01743560 | Approved | Completed |